The Fly

Zymeworks says Hart-Scott-Rodino wait expires for Zanidatamab deal with Jazz

Zymeworks (ZYME) announced that the waiting period under the Hart-Scott-Rodino, HSR, Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals (JAZZ) has expired. The expiration or termination of the HSR waiting period was a condition to Zymeworks’ receipt of a $50M non-refundable upfront payment from Jazz as part of the agreement. Zymeworks anticipates providing Jazz top-line clinical data from Zymeworks’ HERIZON-BTC-01 study before the end of 2022. Should Jazz decide to continue the collaboration following the data readout, a second, one-time payment of $325M to Zymeworks will be due and payable, which Zymeworks expects to receive before the end of 2022.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ZYME:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More